Investment Rating - The report maintains a "Buy" rating for the company with a target price of HKD 16.78 [7][8]. Core Views - The company's revenue for 2024 is projected to be HKD 11.80 billion, reflecting a year-over-year increase of 5.3%, while the net profit attributable to shareholders is expected to be HKD 1.30 billion, a decrease of 20.8% year-over-year. This is slightly below previous expectations due to increased sales and R&D expenses, as well as higher tax expenses compared to the previous year [1][4]. - The second half of 2024 shows a recovery in revenue growth, primarily driven by increased demand for closed-system products due to stricter regulations on non-compliant e-cigarettes in the U.S. and bans on disposable e-cigarettes in several European countries. The company's proprietary brand VAPORESSO is also experiencing rapid growth [1][2]. Summary by Sections Revenue and Profitability - The company's revenue for the first half of 2024 is expected to be HKD 5.04 billion, a decrease of 1.7% year-over-year, while the second half is projected to be HKD 6.76 billion, an increase of 11.2% year-over-year. The net profit for the first half is expected to be HKD 680 million, a decrease of 4.8%, and for the second half, HKD 620 million, a decrease of 33.2% [1][2]. Business Segments - The To B sales revenue for 2024 is projected to be HKD 93.2 billion, a slight decrease of 0.3% year-over-year. The first half is expected to generate HKD 39.2 billion, a decrease of 12.3%, while the second half is expected to recover with HKD 54.0 billion, an increase of 10.7% year-over-year. The U.S. market is expected to see a revenue increase to HKD 21.3 billion in the second half, a quarter-over-quarter increase of 14.6% and a year-over-year increase of 5.2% [2][3]. Cost Structure and Margins - The gross profit margin for 2024 is projected to be 37.4%, a decrease of 1.4 percentage points year-over-year, primarily due to changes in the business structure leading to increased labor and indirect costs. The selling, administrative, and R&D expense ratios are expected to be 7.8%, 7.7%, and 13.2%, respectively, with the increase in selling expenses attributed to the expansion in international markets and new product promotions [3][4]. Future Outlook - The report forecasts net profits for 2025, 2026, and 2027 to be HKD 1.59 billion, HKD 2.21 billion, and HKD 2.85 billion, respectively, with corresponding EPS of HKD 0.26, HKD 0.36, and HKD 0.46. The HNB business is expected to ramp up significantly by 2026, leading to an adjustment in valuation to a PE of 43 times for 2026 [4][6].

Investment Rating - The report maintains a rating of "Buy" for Smoore International (06969.HK) [1] Core Views - The company achieved a revenue of 11.799 billion yuan in 2024, representing a year-on-year increase of 5.6%, while the net profit attributable to shareholders was 1.303 billion yuan, down 20.8% year-on-year [7] - The second half of 2024 saw a revenue of 6.761 billion yuan, up 11.8% year-on-year, but the net profit was 620 million yuan, down 33.2% year-on-year [7] - The gross margin for 2024 was 37.4%, a decrease of 1.3 percentage points, primarily due to changes in product mix [7] - The company is experiencing rapid growth in its proprietary brand business, with revenue reaching 2.475 billion yuan, up 34% year-on-year [7] - The HNB (Heated Not Burned) product line is expected to contribute significantly to profits, with the new product glo Hilo showing positive feedback during trials in Serbia [7] Summary by Sections Financial Performance - Total revenue for 2024 was 11.799 billion yuan, with a year-on-year decline of 8.04% in 2023 [1] - The net profit attributable to shareholders for 2024 was 1.303 billion yuan, down 34.47% from 2023 [1] - Earnings per share (EPS) for 2024 is projected at 0.21 yuan, with a P/E ratio of 59.07 [1] Business Segments - Revenue from proprietary brand business reached 2.475 billion yuan, up 34% year-on-year, while revenue from disposable electronic vapor products was 3.050 billion yuan, down 9.5% [7] - The company’s B2B business revenue for the second half of 2024 was 5.402 billion yuan, up 9.7% year-on-year [7] Market Trends - The report highlights a positive trend in H2 revenue growth due to stricter regulations in Europe and the US, which has led to a recovery in ODM sales [7] - The HNB market is rapidly growing, and the company is diversifying its vaporization business, including beauty and medical applications [7] Profit Forecast - The report adjusts profit forecasts for 2025 to 2027, estimating net profits of 1.636 billion yuan, 2.221 billion yuan, and 2.870 billion yuan respectively [7] - The corresponding P/E ratios for these years are projected at 47, 35, and 27 [7]

Investment Rating - The investment rating for the company is "Buy" (maintained) [6] Core Views - The company is expected to see steady growth in HNB (Heated Not Burned) products in 2025, with significant contributions anticipated in the second half of the year. The potential of the aerosol medical business is also highlighted as a key component of the company's 2030 goals [11] - Revenue for 2024 is projected at 117.99 billion CNY, with a year-on-year growth of 5.3%, while net profit is expected to decline by 20.8% to 13.03 billion CNY [1][11] - The company is focusing on expanding its HNB and aerosol medical product lines, with R&D investments showing significant increases in these areas [3][11] Financial Performance - In 2024, the company achieved a revenue of 117.99 billion CNY, with a net profit of 13.03 billion CNY, resulting in a net profit margin of 11.05% [1] - The company’s revenue for the fourth quarter of 2024 was 34.63 billion CNY, reflecting an 8% increase year-on-year, but a decline in profit by 42% due to high expenses [1] - The projected revenues for 2025, 2026, and 2027 are 128.92 billion CNY, 151.12 billion CNY, and 173.48 billion CNY, respectively, with corresponding net profits of 16.19 billion CNY, 21.21 billion CNY, and 26.59 billion CNY [11][12] Market Potential - The global market for electronic aerosol is expected to reach 91.42 billion USD by 2029, with a CAGR of approximately 7.4% from 2024 to 2029 [4] - The heated not burned market is projected to reach 66.86 billion USD by 2029, with a CAGR of about 10.1% during the same period [4] - The aerosol medical market is anticipated to grow significantly, with the global market for pulmonary drugs and delivery devices expected to reach 93.28 billion USD by 2030 [4]

Investment Rating - The report maintains a "Buy" rating for the company, expecting a price increase of over 15% in the next 6-12 months [3]. Core Views - The company reported a revenue of 11.8 billion yuan for 2024, reflecting a year-on-year increase of 5.3%, while net profit decreased by 20.8% to 1.3 billion yuan. The Q4 revenue was 3.48 billion yuan, up 9.8% year-on-year, but net profit fell by 43.2% to 240 million yuan [1]. - The company's ODM (Original Design Manufacturer) and OBM (Original Brand Manufacturer) revenues showed contrasting trends, with ODM revenue declining slightly by 0.3% to 9.32 billion yuan, while OBM revenue increased by 34.0% to 2.48 billion yuan. In H2, ODM and OBM revenues grew by 9.7% and 13.4% respectively [1]. - The company is experiencing a recovery in its ODM business, particularly in the Chinese market, where revenue increased by 49.6% in H2. However, the European market is facing challenges due to regulations on disposable products [1][2]. - The gross margin for 2024 decreased by 3.9 percentage points to 36.9%, attributed to changes in product mix and rising labor costs. R&D expenses reached 1.57 billion yuan, representing 13.3% of revenue, as the company increased investment in atomization medical and HNB (Heated Not Burned) products [2]. - The HNB market is expected to expand, with potential growth driven by new product launches and market entry strategies. The company is optimistic about its hilo product line following successful trials in Serbia [2]. Summary by Sections Performance Review - The company reported a revenue of 11.8 billion yuan for 2024, with a net profit of 1.3 billion yuan, reflecting a year-on-year decrease of 20.8% [1]. - Q4 revenue was 3.48 billion yuan, up 9.8% year-on-year, while net profit fell by 43.2% to 240 million yuan [1]. Business Analysis - ODM revenue decreased by 0.3% to 9.32 billion yuan, while OBM revenue increased by 34.0% to 2.48 billion yuan [1]. - The Chinese market showed strong growth in ODM, with H2 revenue up 49.6% [1]. - The gross margin decreased to 36.9% due to product mix changes and increased costs [2]. Profit Forecast and Valuation - EPS forecasts for 2025-2027 are 0.24, 0.40, and 0.56 yuan respectively, with corresponding PE ratios of 52, 32, and 22 [3].

思摩尔国际2024年研发开支持续加码 创新成果显著 收益同比增长5.31%至117.99亿元 公告称，加热不燃烧业务是该集团重要的第二条业务增长曲线，2025年是该业务的关键落地阶段。 2025年，该集团支持客户推出的加热不燃烧产品有望在全球更多市场推出。该集团将密切关注用户反 馈，支持客户完成产品优化与迭代。新产品有望自2025年开始逐步为集团贡献更多收入增长机会。同 时，集团在加热不燃烧领域将继续保持研发投入，储备更多的技术和产品解决方案，并积极寻求与其他 行业领先者合作，为第二条增长曲线的落地打下坚实基础。 思摩尔国际(06969)公布2024年业绩，实现收益约117.99亿元，同比增长5.31%;研发开支约15.72亿 元，同比增长约6%;毛利约44.12亿元，同比增长1.64%;净利约13.03亿元，每股基本盈利21.42分，拟派 末期股息每股5港仙。 面向企业客户业务收入约93.24亿元，虽较去年下降约0.3%，但下半年呈现良好恢复趋势，下半年 收入约53.57亿元，较去年增长约9.7%。不同地区业务表现各异，美国市场受FDA监管政策影响，业务 收入下半年实现同比增长;欧洲及其他市场，在监管加强的 ...

Financial Performance - For the fiscal year ending December 31, 2024, the company reported total revenue of RMB 11,798,662 thousand, representing a year-on-year growth of approximately 5.3%[6] - The gross profit for the same period was RMB 4,411,969 thousand, with a gross margin of 37.4%[4] - The company’s net profit for the fiscal year was RMB 1,303,255 thousand, a decrease from RMB 1,645,090 thousand in the previous year[4] - The comprehensive income for the year was approximately RMB 1,416,913 thousand, a decrease of about 9.5% from RMB 1,566,470 thousand in 2023, primarily due to increased sales and R&D expenses[49] - The group reported a segment profit of RMB 1,640,180 thousand for 2024, down from RMB 1,949,597 thousand in 2023, reflecting a decrease of about 15.9%[113] - Basic earnings per share for 2024 were RMB 21.42, down from RMB 27.01 in 2023[95] Revenue Breakdown - Revenue from the proprietary brand business is approximately RMB 2,475,033 thousand, a year-on-year increase of about 34.0%, accounting for about 21.0% of total revenue[16] - Revenue from the enterprise customer business is approximately RMB 9,323,629 thousand, a slight decline of about 0.3%, accounting for about 79.0% of total revenue[16] - In the U.S. market, revenue from enterprise customers is approximately RMB 3,988,170 thousand, a decline of about 2.4%, accounting for about 33.8% of total revenue[21] - Revenue from the Chinese market was approximately RMB 238,751 thousand, representing a year-on-year growth of about 25.1%[24] - The group’s revenue from major customer A was RMB 4,732,568 thousand in 2024, up from RMB 4,582,362 thousand in 2023, contributing over 10% to total revenue[116] Market Position and Share - The company maintained a market share of approximately 13.1% in the global electronic vaporization equipment market for 2024, down from 13.7% in 2023[11] - The company’s proprietary brand "VAPORESSO" has further increased its market share in the open product segment, becoming a leading brand in major global markets[17] - The proprietary brand business in the U.S. market achieved revenue of approximately RMB 424,289 thousand, a year-on-year increase of about 14.0%[17] Research and Development - Research and development expenditure for the review period was approximately RMB 1,572,313 thousand, an increase of about 6.0% from the previous year, accounting for approximately 13.3% of revenue[25] - The company achieved significant breakthroughs in research and development for its heating-not-burning and medical vaporization businesses during the review period[8] - The company plans to enhance its R&D focus on heated tobacco products and aerosol medical products as key directions for 2025[44] Operational Efficiency - The company achieved significant progress in production operations, enhancing manufacturing competitiveness through collaboration across teams and optimizing production processes[35] - The group aims to enhance manufacturing competitiveness and optimize production processes, with a focus on resource integration and cost reduction[47] Expenses and Costs - Distribution and selling expenses increased by approximately 74.7% to about RMB 919,552 thousand, representing about 7.8% of revenue, driven by increased marketing investments in global operations and new product launches in the Chinese market[60] - Administrative expenses rose by approximately 5.4% to about RMB 914,109 thousand, maintaining a stable percentage of about 7.7% of revenue[63] - R&D expenses grew by approximately 6.0% to about RMB 1,572,313 thousand, accounting for about 13.3% of revenue, with significant investments in the fields of atomization medical and heated non-combustible products[66] Future Outlook - The global electronic vaporization product market is projected to reach approximately $91.42 billion by 2029, with a compound annual growth rate (CAGR) of about 7.4% from 2024 to 2029[37] - The global heated tobacco market is expected to reach around $66.86 billion by 2029, with a CAGR of approximately 10.1% from 2024 to 2029[39] - The company is committed to building a leading global vapor technology platform, focusing on electronic vaporization, heated non-combustible products, and medical vaporization solutions[36] Corporate Governance - The company maintained a governance structure that complies with the Hong Kong Stock Exchange's corporate governance code, with a board comprising eight directors, including three independent non-executive directors[143] - The board of directors is committed to ensuring transparency and accountability to all shareholders, with regular reviews of governance effectiveness[145] Shareholder Communication - The company has established a shareholder communication policy to ensure effective communication with shareholders[152] - The company encourages shareholders to express their opinions and suggestions during the annual general meeting[150]

证券研究报告 公司研究 [Table_ReportType] 公司点评报告 | [Table_StockAndRank] 思摩尔国际(6969.HK) | | --- | | 投资评级 无评级 | | 上次评级 无评级 | [Table_Author] 姜文镪 新消费行业首席分析师 执业编号：S1500524120004 邮箱：jiangwenqiang@cindasc.com 相关研究 信达证券股份有限公司 CINDA SECURITIES CO.,LTD 北京市西城区宣武门西大街甲127号金隅大厦B 座 邮编：100031 [Table_Title] 砥砺前行，长期主义铸造价值成长 [Table_ReportDate] 2025 年 3 月 12 日 [Table_S 事件：近日公司旗下科技护肤品牌 ummary] MOYAL 岚至取得二类医疗器械证书，并 于 2 月 26 日在广西贺州高新区产业开发区举行"无创雾化高端医疗器械项 目投产仪式"，公司副总裁、美容事业部总裁吴俊兰表示新工厂将全面承接 MOYAL 岚至 TPS 技术平台的医疗器械生产与制造。公司预计 25 年产值有 望达 1.5 亿元，3 年 ...

证券研究报告 公司研究 [Table_ReportType] 公司点评报告 | [Table_StockAndRank] 思摩尔国际(6969.HK) | | --- | | 投资评级 无评级 | | 上次评级 无评级 | [Table_Author] 姜文镪 新消费行业首席分析师 执业编号：S1500524120004 邮箱：jiangwenqiang@cindasc.com 相关研究 IQOS 有望发力美国地区，美国或将成为核心 HNB 市场。2024 年 IQOS 已 解决专利纠纷、重返美国，目前仍处于消费者教育阶段，我们预计新品 ILUMA 在 25H2 通过 PMTA 后，菲莫将正式发力美国市场。2023 年美国总 烟民人数为 4340 万人（卷烟+雾化），根据我们测算，美国消费能力强、新 型烟草教育程度高，假设美国 2030 年 HNB 渗透率达到 30%（HNB 烟民/ 卷烟+雾化+HNB），每年烟弹消耗量有望增长至 800-900 亿支（2023 年全 球烟弹消耗量为 1600 亿支），或将成为比肩日本的核心市场。 英美新品放量可期，全球化进展加速。公司 24 年底已在塞尔维亚推出全新 产品 ...

[Table_ReportType] 公司点评报告 | [Table_StockAndRank] 思摩尔国际(6969.HK) | | --- | | 投资评级 无评级 | | 上次评级 无评级 | [Table_Author] 姜文镪 新消费行业首席分析师 执业编号：S1500524120004 邮箱：jiangwenqiang@cindasc.com 证券研究报告 公司研究 相关研究 信达证券股份有限公司 CINDA SECURITIES CO.,LTD 北京市西城区宣武门西大街甲127号金隅大厦B 座 邮编：100031 [Table_Title] 砥砺前行，长期主义铸造价值成长 [Table_ReportDate] 2025 年 3 月 12 日 [Table_S 事件：近日公司旗下科技护肤品牌 ummary] MOYAL 岚至取得二类医疗器械证书，并 于 2 月 26 日在广西贺州高新区产业开发区举行"无创雾化高端医疗器械项 目投产仪式"，公司副总裁、美容事业部总裁吴俊兰表示新工厂将全面承接 MOYAL 岚至 TPS 技术平台的医疗器械生产与制造。公司预计 25 年产值有 望达 1.5 亿元，3 年 ...

Investment Rating - The report assigns an "Outperform" rating for the company [1]. Core Insights - The company is positioned as a global leader in compliant vaping technology, with significant growth potential in the Heat-Not-Burn (HNB) segment [3]. Market Overview - The global new tobacco market is estimated at approximately $76.9 billion in 2023, with HNB and e-cigarettes accounting for 45% and 28% of the market, respectively [4][14]. - The penetration rate of new tobacco products among smokers is only 8.1%, indicating substantial room for growth [15]. Regional Analysis - **United States**: The largest market for new tobacco, valued at $24.8 billion in 2023, with HNB market potential expected to increase following patent resolutions between major tobacco companies [23][27]. - **Europe**: The market reached $31 billion in 2023, with a high acceptance of HNB products, particularly in Eastern Europe [5]. - **Japan and South Korea**: Dominant markets for HNB, with respective market sizes of $11.7 billion and $2.6 billion in 2023, showing strong growth trends [5]. Competitive Landscape - Major tobacco companies like PMI and BAT are leading the transition to new tobacco products, with significant market shares in the HNB segment [6]. - The company holds approximately 13.7% of the global e-vapor device market, with a focus on expanding its HNB product offerings [7]. Financial Projections - The company is projected to achieve net profits of $1.304 billion, $1.578 billion, and $2.040 billion for the years 2024, 2025, and 2026, respectively, with corresponding EPS of 0.21, 0.26, and 0.33 [8]. - The estimated market value for the company is expected to reach between HKD 714 billion and HKD 1,020 billion by 2025, with a PE ratio ranging from 45 to 65 [8]. Growth Drivers - The growth is driven by the industry's beta benefits and the anticipated regulatory clarity, alongside the commercialization of HNB products for major clients [8].